Download MendeleyIdentification of GDC-1971 (RLY-1971), a SHP2 Inhibitor Designed for the Treatment of Solid Tumors.
Taylor, A.M., Williams, B.R., Giordanetto, F., Kelley, E.H., Lescarbeau, A., Shortsleeves, K., Tang, Y., Walters, W.P., Arrazate, A., Bowman, C., Brophy, E., Chan, E.W., Deshmukh, G., Greisman, J.B., Hunsaker, T.L., Kipp, D.R., Saenz Lopez-Larrocha, P., Maddalo, D., Martin, I.J., Maragakis, P., Merchant, M., Murcko, M., Nisonoff, H., Nguyen, V., Nguyen, V., Orozco, O., Owen, C., Pierce, L., Schmidt, M., Shaw, D.E., Smith, S., Therrien, E., Tran, J.C., Watters, J., Waters, N.J., Wilbur, J., Willmore, L.(2023) J Med Chem 66: 13384-13399
- PubMed: 37774359
- DOI: https://doi.org/10.1021/acs.jmedchem.3c00483
- Primary Citation of Related Structures:
8T6D, 8T6G, 8T7Q, 8T8Q - PubMed Abstract:
Protein tyrosine phosphatase SHP2 mediates RAS-driven MAPK signaling and has emerged in recent years as a target of interest in oncology, both for treating with a single agent and in combination with a KRAS inhibitor. We were drawn to the pharmacological potential of SHP2 inhibition, especially following the initial observation that drug-like compounds could bind an allosteric site and enforce a closed, inactive state of the enzyme. Here, we describe the identification and characterization of GDC-1971 (formerly RLY-1971), a SHP2 inhibitor currently in clinical trials in combination with KRAS G12C inhibitor divarasib (GDC-6036) for the treatment of solid tumors driven by a KRAS G12C mutation.
Organizational Affiliation:
Relay Therapeutics, Inc., 399 Binney St., Cambridge,, Massachusetts 02139, United States.
